CE18 - Innovation biomédicale

Innovative Plasmodium G-quadruplexes ligands as new potential antimalarial drugs – MAG4

Submission summary

Our project aims at an original strategy to propose novel and innovative antimalarial drugs based on the design of small molecules that specifically target the G-quadruplexes structures present in the mitochondrial genome of Plasmodium falciparum.
Guanine-rich DNA and RNA sequences can fold into four-stranded non-canonical secondary structures called G-quadruplexes. The genome of malaria parasite, Plasmodium falciparum, is characterized by its extreme AT rich sequence (> 80 %). Given the A/T bias, only few regions of the parasite genome have the potential to form G4 structures. Nevertheless, the presence of G4 structures in Plasmodium has been confirmed by the use of a specific G4-detecting antibody. Interestingly, genome-wide analysis of nuclear and mitochondrial DNA of the Plasmodium parasite shows a higher G4 motif density in mitochondria in comparison to the nuclear DNA.
Our preliminary data, resulting from an active collaboration between partners 1 and 2 showed a very effective and selective activity of some acridine-based G-quadruplex (G4) ligands against Plasmodium falciparum. We tested 8 different G4 ligands and we demonstrated that RHPS4, a potent and selective G4 ligand, has a substantial antimalarial activity (IC50 = 75 nM) on multidrug resistant P. falciparum parasites strain. Moreover, we showed that RHPS4 exhibit a high selectivity for Plasmodium with respect to human cells with selectivity indexes (IC50 human cell/IC50 Plasmodium) ranging from 100 to more than 300. Strikingly, using a classical qPCR approach, we have also demonstrated that the treatment of P. falciparum with RHPS4 causes a drastic decrease of the mitochondrial DNA copy relative to global amount of Plasmodium genomic DNA.
From these data, the objective of this project is the research and development of RHPS4 derivatives as antimalarial-drugs acting through the stabilization of G-quadruplex structures present in the mitochondrial genome of Plasmodium falciparum.

Project coordination

Dennis Gomez (INSTITUT de PHARMACOLOGIE et de BIOLOGIE STRUCTURALE)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

I2BC Institut de Biologie Intégrative de la Cellule
LCC LABORATOIRE DE CHIMIE DE COORDINATION
IPBS INSTITUT de PHARMACOLOGIE et de BIOLOGIE STRUCTURALE

Help of the ANR 576,782 euros
Beginning and duration of the scientific project: October 2022 - 48 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter